Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 26, 2015
Pharmacy Choice - News - Over-the-Counter Drugs - April 26, 2015

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 31     Next >>     Go To Page:

4/26/15 - United States : Mylan Makes Offer to Acquire Perrigo [TendersInfo (India)]
Davis Polk is advising Goldman Sachs as lender and financial adviser to Mylan N.V. in connection with its proposal to acquire Perrigo Company plc for $60 in cash and 2.2 Mylan shares per Perrigo share. Perrigo is a leading global health care supplier that develops, manufactures and distributes over-the-counter and prescription pharmaceuticals,...
4/25/15 - Mylan raises bid for fellow drugmaker; Perrigo says 'no' [The Pittsburgh Tribune-Review]
April 24 Mylan NV launched a hostile takeover bid for fellow generic drug maker Perrigo Co., telling the company's stockholders Friday it will pay them $31.2 billion if they tender their shares. The board of Ireland- based Perrigo, which makes over-the-counter medicines and nutritional products, urged its shareholders to take no action, arguing t
4/24/15 - "Smoking Cessation Device" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Health& Medicine Week A patent application by the inventor Park, Andrew Chunkil, filed on October 1, 2014, was made available online on April 9, 2015, according to news reporting originating from Washington, D.C., by NewsRx correspondents. "According to the U.S. Food and Drug Administration, tobacco use is
4/24/15 - Actavis Announces Topline Phase 3 Clinical Trial Results for Single-Dose DALVANCE (dalbavancin) in the Treatment of ABSSSI
Single-dose dalbavancin has shown positive results for the treatment of serious skin infections and can be an important new treatment option for patients, "said David Nicholson, Actavis Executive Vice President, Global Brands R&D. Actavis plans to file a supplemental New Drug Application with these data in Q3 2015.. This study was conducted pursuan
4/24/15 - FDA ISSUES WARNINGS ON MISLABELED SUPPLEMENTS FOLLOWING BLUMENTHAL AND DURBIN'S CALL TO ACTION
Yesterday, the FDA issued warning letters to five companies regarding eight products which list BMPEA as a dietary ingredient, and some of which identify the source of this stimulant as "acacia rigidula." The FDA announcement is available at: http://www.fda.gov/Food/DietarySupplements/QADietarySupplements/ucm443790. htm. "Last week, we told the FD
4/24/15 - Mylan makes official bid for Perrigo in generic drug contest
Generic drugmaker Mylan is making official its offer for over-the-counter medicines maker Perrigo as it remains at the center of a three-way battle: Mylan wants to buy Perrigo, while a larger rival wants to buy Mylan. Perrigo has already rejected Mylan's offer and reiterated Friday it feels the bid, worth more than $30 billion, is too low. By bu
4/24/15 - NEUROMETRIX, INC. - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion of our financial condition and results of operations in conjunction with our financial statements and the accompanying notes to those financial statements included elsewhere in this Quarterly Report on Form 10- Q. This discussion contains forward-looking statements that involve risks and uncertainties.
4/23/15 - Actavis Launches AVYCAZ? (Ceftazidime-Avibactam) Anti-Infective In U.S.
"In light of the urgent medical need in the U.S. for new antimicrobial treatments that address some of the most difficult to treat pathogens, Actavis increased the company's manufacturing focus to ensure AVYCAZ would be available as soon as possible following FDA approval," said William Meury, President, Actavis Branded Pharma. AVYCAZ is part of Ac
4/23/15 - Active Pharmaceutical Ingredients Market: - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
This report analyses the global market for active pharmaceutical ingredients for the period from 2012 to 2020. The market has been analyzed on the basis of type of API manufacturing, type of active pharmaceutical ingredients, type of drugs, therapeutic areas, and by geography. The global API market is analyzed on the basis of therapeutic areas na
4/23/15 - FDA Issues Warnings On Mislabeled Supplements Following Senators' Call To Action
Earlier today, the FDA issued warning letters to five companies regarding eight products which list BMPEA as a dietary ingredient, and some of which identify the source of this stimulant as "acacia rigidula." The FDA announcement is available here http://www.fda.gov/Food/DietarySupplements/QADietarySupplements/ucm443790. htm. "Last week, we told t
4/23/15 - MOH warns against buying medicines on the Internet [XPRESS (United Arab Emirates)]
The Ministry of Health has warned the public against buying medicines and food supplements from online pharmacies and outlets as over 95 per cent of them are illegal. Speaking on the sidelines of the Emirates International Conference on Combating Drug Counterfeiting in Dubai on April 20, Dr Amin Hussain Al Amiri, assistant undersecretary for public
4/23/15 - Mylan pressured to accept $40B buyout bid by Teva [The Pittsburgh Tribune-Review]
Standard& Poor's Ratings Services said it could downgrade Mylan's credit rating if it doesn't accept Teva Pharmaceutical Industries Ltd.' s unsolicited offer and instead accumulates debt in pursuit of a deal with fellow generic drugmaker Perrigo Co.. Ireland- based Perrigo, a maker of store-brand over-the-counter health and nutritional products,...
4/23/15 - Perrigo spurning Mylan's advance [Pittsburgh Post-Gazette]
April 23 As speculation percolated Wednesday that local generic drug giant Mylan was preparing to raise its spurned, unsolicited bid for rival drugmaker Perrigo Co., Mylan's intended prey made it clear that such a deal would continue to be a tough sell. So it's not only price "that caused Perrigo's board to reject Mylan's initial $205- a-share of
4/22/15 - Axxess Pharma Signs Major Manufacturing, Marketing and Distribution Agreement with Chinese Manufacturer
Axxess Pharma projects minimum sales of $525,000 USD in the first year and $4,308,000 USD in the initial 5 year term of the license. "This deal represents a major milestone for Axxess Pharma, and validates the value of our Intellectual Property. Axxess Pharma Inc. is a Nevada Corporation operating through its wholly owned Canadian Subsidiary: Axxe
4/22/15 - CASMED Receives FDA Approval for FORE-SIGHT ELITE; Provectus Opens Patient Enrollment of PV-10 for Melanoma
Below is a look at some of the headlines for companies that made news in the healthcare sector on April 15, 2015.{ nfg} CAS Medical Systems, Inc., a leader in medical devices for non-invasive patient monitoring, announces receipt of an expanded label for its FORE-SIGHT ELITE oximeters from the FDA to include its new medium and small sensors for
4/22/15 - Nutra Pharma Announces Nyloxin(R) Distribution Plans for China
Nutra Pharma Corporation, a biotechnology company that is developing treatments for Multiple Sclerosis, Human Immunodeficiency Virus, Adrenomyeloneuropathy and Pain, announced today that they have engaged the Vancouver Commodities Group to begin the process of identifying and vetting potential distributors in China for the Company's...
4/22/15 - Orexigen Announces Receipt of Paragraph IV Certification Notice
Orexigen Therapeutics, Inc. today announced that Orexigen and North American partner Takeda Pharmaceuticals have received notification of a Paragraph IV certification for certain patents for Contrave which are listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. Orexigen and Takeda plan to...
4/22/15 - Purdue Pharma Names J. Alan Butcher Senior Vice President of Licensing & Business Development
Release date- 21042015- Stamford, Conn.- Purdue Pharma, a leading specialty pharmaceutical company, today announced that Alan Butcher has joined the company as Senior Vice President of Licensing& Business Development. Since 2012, he has been Vice President of Business Development at Shire Pharmaceuticals. Prior to joining Shire, Alan was Vice Presi
4/22/15 - West Michigan drug maker rejects acquisition attempt [Detroit Free Press]
April 21 Perrigo, a generic drug maker with deep roots in west Michigan, has rejected an acquisition attempt by an England drug giant that is now facing its own acquisition bid. Consolidation fever is peaking in the generic drug business amid a flurry of activity centering a trio of companies: Israel- based Teva Pharmaceutical Industries, England
4/21/15 - FDA weighs crackdown on homeopathic remedies: 'They're mostly sugar pills'
They re mostly sugar pills, said Jim Underdown, the executive director of the Los Angeles branch of the Center for Inquiry, a nonprofit that advocates secularism and science, and made a presentation to the FDA panel on Monday. People seem to think they actually have medicinal value, but all the science points to that not being true.. Th
4/21/15 - FDA: Safety problems prompted review of homeopathic remedies
Similar to dietary supplements, the FDA does not review the safety or effectiveness of homeopathic remedies before they are sold. In perhaps the most serious case, in 2009 the FDA ordered the maker of Zicam to stop marketing three products that contained zinc gluconate. In 2010, the FDA warned about reports of toxicity in children taking Hyland Hom
4/21/15 - MHW to set up 'pharmaceutical cloud'
Hospitals and factories can begin submitting their product information starting from July 1, said the FDA's medicine chief Liu Li- ling, further noting that the ministry aims to connect the pharmaceutical cloud with other related cloud databases, such as those organizing information held by enterprises, manufacturers and medicine circulation by nex
4/21/15 - Perrigo rejects $29B offer from generic drugmaker Mylan
Over-the-counter medicines maker Perrigo said Tuesday it is turning down a buyout offer from generic drugmaker Mylan that valued the company at $205 per share, or almost $29 billion, because it's too low. Perrigo said that Mylan's offer undervalues its business, including its product pipeline and its recent purchase of Belgium's Omega Pharma, on
4/21/15 - Perrigo takes 3Q loss, says it won't take Mylan's $29B bid
Irish drug and over-the-counter ingredients maker Perrigo Co. said Tuesday it took a loss in its fiscal third quarter as it prepared to buy a Belgian competitor. Perrigo's fiscal third quarter ended on March 28, and the company closed its $4.48 billion purchase of Omega Pharma on March 30. Perrigo said Tuesday that that offer is too low because
4/21/15 - Pharma and Healthcare Social Media Marketing Market: Global Industry Analysis and Opportunity Assessment 2015 - 2025: FMI
Future Market Insights has announced the addition of the "Pharma and Healthcare Social Media Marketing Market: Global Industry Analysis and Opportunity Assessment 2015- 2025" report to their offering.London, UK 04/21/2015 Social media platforms refer to the interaction among the people that involves creation, sharing and exchange of informati
Articles(s): 1 - 25 of 31     Next >>     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415